Catalog No.
KGD76501
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for Romiplostim has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Romiplostim present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled antibody specific for Romiplostim is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Romiplostim bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Romiplostim concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
11.72 - 750 pg/mL
Sensitivity
11.31 pg/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (pg/mL)
|
355.1
|
74.7
|
17.5
|
350.0
|
79.3
|
23.1
|
|
Standard deviation
|
13.4
|
5.8
|
1.4
|
11.8
|
4.1
|
3.2
|
|
CV (%)
|
3.8
|
7.8
|
8.2
|
3.4
|
5.1
|
13.9
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 12 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Alternative Names
CAS: 267639-76-9, romiplostim (Nplate)
Background
Romiplostimis a fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
High-dose romiplostim for donor-type aplasia., PMID:40504447
Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott-Aldrich syndrome patients., PMID:40400288
THPO promoter mutation: a familial study on congenital amegakaryocytic thrombocytopenia., PMID:40386912
The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering., PMID:40384450
Systemic Lupus Erythematosus with Refractory Immune Thrombocytopenia Progressing to Catastrophic Anti-Phospholipid Syndrome During Thrombopoietin Receptor Agonist Therapy: A Case Report., PMID:40364121
A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks., PMID:40323132
Robotic Splenectomy as a Salvage Therapy Post Failed Splenic Embolization in Chronic Immune Thrombocytopenic Purpura Due to the COVID-19 Vaccine., PMID:40314051
Utility and Safety of Romiplostim as an Alternative to Platelet Transfusion for Neonates., PMID:40302050
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK., PMID:40276091
Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data., PMID:40196346
Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations., PMID:40161263
Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA., PMID:40101243
A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists., PMID:40098741
[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]., PMID:40044178
Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment., PMID:40040262
Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study., PMID:40027000
Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System., PMID:40016824
Avatrombopag for the Treatment of Immune Thrombocytopenia., PMID:39905676
Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports., PMID:39894785
Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy., PMID:39880098
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia., PMID:39852180
Romiplostim Reduces Platelet Transfusion Needs in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation., PMID:39840153
Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report., PMID:39802214
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies., PMID:39780402
Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia., PMID:39702972
Mitani K, Lee JW, Jang JH, et al. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study. Blood Adv. 2024;8(6):1415-1419., PMID:39625711
Role of Serum Interleukin-10 and Interleukin-27 Levels in the Prognosis of Immune Thrombocytopenia in Iraqi Children., PMID:39582823
Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study., PMID:39581951
The Establishment of a Novel Murine Model of Immune Thrombocytopenia in Pregnancy and the Impacts of Thrombopoietin Receptor Agonist on Platelet Production., PMID:39539867
[Pharmacotherapy for aplastic anemia]., PMID:39505555
A second chance for avatrombopag in chemotherapy-induced thrombocytopenia., PMID:39491815
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)., PMID:39394928
[New drugs for the treatment of primary immune thrombocytopenia]., PMID:39358266
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies., PMID:39348667
Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings., PMID:39342544
Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag., PMID:39302624
Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review., PMID:39290805
Ruptured Ovarian Cyst Leading to Massive Spontaneous Intraperitoneal Hemorrhage in Chronic Immune Thrombocytopenic Purpura (ITP): Successful Nonsurgical Intervention., PMID:39280513
Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?, PMID:39228082
Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China., PMID:39220274
Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report., PMID:39175509
Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?, PMID:39162982
Peptibodies: Bridging the gap between peptides and antibodies., PMID:39142490
Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature., PMID:39135303
Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report., PMID:39130867
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management., PMID:39105265
Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway., PMID:39102877
Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador., PMID:39079145
For research use only. Not for human or drug use.
